THE POTENTIAL ADVANTAGES OF LIPID NANOPARTICLES IN TREATMENT OF ACNE

  • Vipul Ajit Sansare Department of Pharmaceutics, Indira Institute of Pharmacy, Sadavali
  • Abhijeet Mohan Kanavaje Department of Pharmaceutics, Indira Institute of Pharmacy, Sadavali
DOI https://doi.org/10.31069/japsr.v2i3.2

Abstract

Acne is a disfiguring disorder of the skin with significant cosmetic morbidity that may lead to serious psychological and social dysfunction. The skin disease comes in two forms. The most well-known form is Acne vulgaris (referred to as acne), which mostly manifests in teens but may continue into the early 20s. The second form is called Acne rosacea (referred to as rosacea) and mostly affects 30- to 60-year-olds. The two forms, despite sharing a common prefix, are quite unrelated in their respective pathophysiology, have different approaches to treatment and hence are considered two separate conditions. The conventional drug delivery system is efficient in the management of acne but poor patient compliance and adverse effects limit its efficacy. Lipid nanoparticles are novel nano lipid carriers made from biocompatible lipid which reduces toxicity; improve physical stability, skin hydration, and film formation. Furthermore, lipid nanoparticles protect the encapsulated drug from degradation. Thus current review focused on the potential use of lipid nanoparticles for the management of acne.

Keywords: Acne, Rosacea, Solid lipid nanoparticles, Topical drug delievry, Nanolipids, Acne vulgaris

Downloads

Download data is not yet available.

References

1. Zouboulis C, Eady A, Philpott M, Goldsmith L, Orfanos C, Wc Cunliffe RR.What is the pathogenesis of acne ? Exp Dermatology. 2005; 14(5):143-152.
2. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006; 78:97–100.
3. Whitfeld M, Gunasingam N, Leow LJ, Shirato K, Preda V. Staphylococcus epidermidis: A possible role in the pustules of rosacea. Journal of American Academy of Dermatology. 2011; 64(1):49-52.
4. Yu M, Ma H, Lei M, Li N, Tan F. In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties. European Journal of Pharmaceutics and Biopharmaceutics. 2014; 88(1):92-103.
5. Palombo-kinne E, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0. 030 mg ethinylestradiol / 2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol / 2 mg cyproterone acetate. Contraception. 2009; 79(4):282-289.
6. Yang D, Pornpattananangkul D, Nakatsuji T, Chan M, Carson D, Huang CM, Zhang L. Biomaterials The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials. 2009; 30(30):6035-6040.
7. Ellis CN, Millikan LE, Smith EB, Chalker DM, Swinyer LJ, Katz IH, Berger RS, MillsOH, Baker M. Comparison of adapalene 0.1% solution and tretinoin 0.025%gel in the topical treatment of acne vulgaris. British Journal of Dermatology. 1998; 139(52):41-47.
8. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D, Global Alliance to Improve Outcomes in Acne. Management of Acne. Journal of American Academy of Dermatology. 2003; 33(1):1-37.
9. Leyden JJ, Philadelphia JJL. Topical treatment of acne vulgaris : Retinoids and cutaneous irritation. Journal of American Academy of Dermatology. 1998; 38(4):1-4.
10. Garg T. Current nanotechnological approaches for an eff ective delivery of bio-active drug molecules in the treatment of acne. Artificial Cells, Nanomedicine and Biotechnol. 2016; 44(1): 98-105.
11. Elsaie ML, Choudhary S. Updates on the Pathophysiology and Management of Acne Rosacea. Postgraduate Medicine. 2009; 121(5):178-186.
12. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Journal of American Academy of Dermatology. 2002; 46(4):584-587.
13. Cohen AF, Tiemstra JD. Diagnosis and Treatment of Rosacea. Journal of American Board of Family Practice. 2002; 15(3):214-217.
14. Zuber TJ. ROSACEA. Dermatology. 2000; 27(2):309-318.
15. Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinology. 2017; 9(1):1-10.
16. Krautheim A, Gollnick H. Transdermal Penetration of Topical Drugs Used in the Treatment of Acne. Clinical Pharmacokinetics. 2003; 42(14):1287-1304.
17. Reinholz M, Tietze JK, Kilian K, Schaller M, Schöfer H, Lehmann P, Zierhut M, Klövekorn W, Ruzicka T, Schauber J. Rosacea – S1 Guideline 1. Journal of the German Society of Dermatology. 2013; 11(8):768-780.
18. Date AA, Naik B, Nagarsenker MS. Novel Drug Delivery Systems : Potential in Improving Topical Delivery of Antiacne Agents.Skin Pharmacology and Physiology. 2006; 19(1):2-16.
19. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M, Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0 Æ 5 % is a novel treatment for moderate to severe facial erythema of rosacea : results of two multicentre , randomized and vehicle-controlled studies. British Journal of Dermatology. 2012; 166(3):633-641.
20. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. International Journal of Pharmaceutics. 2004; 278(1):71-77.
21. Wretlind A. Development of Fat Emulsions. Journal of Parenteral and Enternal Nutrition. 1981;5(3):230-235.
22. Schwarz C, Mehnert W, Lucks JS, Miiller RH. Solid lipid nanoparticles ( SLN ) for controlled drug delivery . I. Production, characterization and sterilization. Journal of Controlled Release. 1994; 30(1):83-96.
23. Yoon G, Woo J, Yoon PI. Solid lipid nanoparticles ( SLNs ) and nanostructured lipid carriers ( NLCs ): recent advances in drug delivery. Journal of Pharmaceutical Investigation. 2013; 43(5):353-362.
24. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens : in vitro release and in vivo skin penetration. Journal of Controlled Release. 2002; 81(3):225-233.
25. Vijayan V, Aafreen S, Sakthivel S, Reddy KR. Formulation and characterization of solid lipid nanoparticles loaded Neem oil for topical treatment of acne. Journal of Acute Disease. 2013; 2(4):282-286.
26. Gavini E, Sanna V, Sharma R, Juliano C, Usai M, Marchetti M, Karlsen J, Giunchedi P. Solid Lipid Microparticles ( SLM ) Containing Juniper Oil as Anti-Acne Topical Carriers : Preliminary Studies Solid Lipid Microparticles ( SLM ) Containing Juniper Oil as Anti-Acne Topical Carriers : Preliminary Studies. Pharmaceutical Development and Technology. 2005; 10(4):479–487.
27. Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Durán N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids and Surfaces B, Biointerfaces. 2012; 93:36-40.
28. Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles ( SLNs ) for topical treatment of acne. Colloids and Surfaces B, Biointerfaces. 2013;105:67-74.
29. Silva EL, Carneiro G, De Araújo LA, Trindade Mde J, Yoshida MI, Oréfice RL, Farias Lde M, De Carvalho MA, Dos Santos SG, Goulart GA, Alves RJ, Ferreira LA. Solid Lipid Nanoparticles Loaded with Retinoic Acid and Lauric Acid as an Alternative for Topical Treatment of Acne Vulgaris. Journal of Nanoscience and Nanotechnology. 2015;15(1):792–799.
30. Pokharkar VB, Mendiratta C, Kyadarkunte AY, Bhosale SH BG. Skin delivery aspects of benzoyl peroxide-loaded solid lipid nanoparticles for acne treatment. Therapeutic Delivery. 2014; 5(6):635-652.
Statistics
1876 Views | 1963 Downloads
How to Cite
Sansare, V., and A. Kanavaje. “THE POTENTIAL ADVANTAGES OF LIPID NANOPARTICLES IN TREATMENT OF ACNE”. Journal of Applied Pharmaceutical Sciences and Research, Vol. 2, no. 3, Oct. 2019, pp. 6-13, doi:10.31069/japsr.v2i3.2.
Issue
Volume 2, Issue 3, 2019
Section
Review Articles

All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)

Under this license, you are free to:

  • Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt- remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes .
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.

Licensing policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.